Cilostazol detailed information: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Gerald Chi (talk | contribs)
CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
17,702 edits
m Changed protection level for "Cilostazol detailed information" ([Edit=Allow only autoconfirmed users] (expires 23:53, 12 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 23:53, 12 February 2014 (UTC)))
Ahmed Zaghw (talk | contribs)
nocaptcha
4,404 edits
No edit summary
Line 1: Line 1:
{{drugbox |
__NOTOC__
| IUPAC_name = 6-[4-(1-cyclohexyl-1''H''-tetrazol-5-yl)butoxy]-<br>3,4-dihydro-2(1''H'')-quinolinone
| image = Cilostazol.svg
| width = 300px
| CAS_number = 73963-72-1
| ATC_prefix =
| ATC_suffix =
| PubChem = 2754
| DrugBank = APRD00155
| C=20 | H=27 | N=5 | O=2
| molecular_weight = 369.46 g/mol
| bioavailability =
| protein_bound = 95–98%
| metabolism = [[Liver|Hepatic]] ([[CYP2C19]]- and [[CYP3A4]]-mediated)
| elimination_half-life = 11–13 hours
| excretion = renal
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category = 
| legal_AU =      <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK =      <!-- GSL        / P      / POM / CD -->
| legal_US =      <!-- OTC                  / Rx-only  -->
| legal_status =
| routes_of_administration = Oral
}}
{{CMG}}


{{Cilostazol}}


{{CMG}}; {{AE}} {{AZ}}


'''Cilostazol''' ({{pronEng|sɨˈlɒstəzɒl}}) is a [[medication]] used in the alleviation of the [[symptom]] of [[intermittent claudication]] in individuals with [[peripheral vascular disease]].  It is manufactured by [[Otsuka Pharmaceutical Co.]] under the [[trade name]] '''Pletal'''.
'''''For patient information, click <u>[[Cilostazol (patient information)|here]]'''''</u>.


Although drugs similar to cilostazol have increased the risk of death in patients with [[congestive heart failure]], studies of significant size have not addressed people without the disease.
==Overview==


Cilostazol is a selective [[cAMP]] [[phosphodiesterase inhibitor]].  It inhibits platelet aggregation and is a direct arterial vasodilator.  Its main effects are dilation of the [[artery|arteries]] supplying [[blood]] to the legs and decreasing [[platelet]] [[coagulation]].
==Category==
PLETAL
==US Brand Names==


==Usage==
==FDA Package Insert==
Cilostazol is approved for the treatment of [[intermittent claudication]].  The typical dose is 100&nbsp;[[milligram|mg]] twice a day.  The effects may take as much as 3 months to be evident.


==Interactions and side effects==
'''| [[Cilostazol indications and usage|Indications and Usage]]'''
Drugs that interact with cilostazol include [[itraconazole]], [[erythromycin]], [[ketoconazole]], [[diltiazem]], and [[omeprazole]].  [[Grapefruit]] [[grapefruit juice|juice]] interacts with the drug; other [[citrus]] juices do not. 
'''| [[Cilostazol dosage and administration|Dosage and Administration]]'''
'''| [[Cilostazol dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Cilostazol contraindications|Contraindications]]'''
'''| [[Cilostazol warnings|Warnings and Precautions]]'''
'''| [[Cilostazol adverse reactions|Adverse Reactions]]'''
'''| [[Cilostazol drug interactions|Drug Interactions]]'''
'''| [[Cilostazol use in specific populations|Use in Specific Populations]]'''
'''| [[Cilostazol overdosage|Overdosage]]'''
'''| [[Cilostazol description|Description]]'''
'''| [[Cilostazol clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Cilostazol nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Cilostazol clinical studies|Clinical Studies]]'''
'''| [[Cilostazol how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Cilostazol patient counseling information|Patient Counseling Information]]'''
'''| [[Cilostazol labels and packages|Labels and Packages]]'''


Possible side effects of cilostazol include [[headache]], [[diarrhea]], abnormal [[stool]]s, increased [[heart rate]], and [[palpitations]].
==Mechanism of Action==
 
==Important note==
Cilostazol, clearly effective for a debilitating condition whose current treatment is often inadequate, is a member of a pharmacologic class that is dangerous to people with severe heart failure and unstudied in other people. Cilostazol has been studied in people without heart failure, without evidence of harm, but much more data would be needed to determine that there is no risk at all. Although cilostazol would not be approvable for a trivial condition the Cardio-Renal Advisory Committee and FDA concluded that fully informed patients and physicians should be able to choose to use it to treat intermittent claudication. Patient and physician labeling will describe the basis for concern and the incomplete information available.<ref>{{cite web | url = http://www.fda.gov/cder/news/cilostazol/approval.htm | date = August 11 1999 | accessdate = 2007-04-30 | author = [[Center for Drug Evaluation and Research]] | title = Approval of Cilostazol | publisher = U.S. [[Food and Drug Administration]]}}</ref>
 
==External links==
* [http://www.drugdigest.org/DD/DVH/Uses/0,3915,733|Pletal,00.html Supplementary information provided by Drug Digest]


==References==
==References==
{{Reflist}}
{{Antithrombotics}}
[[Category:Antiplatelet drugs]]
[[Category:Vasodilators]]
[[Category:Tetrazoles]]
[[pt:Cilostazol]]


{{Reflist|2}}


{{WH}}
[[Category:Drugs]]
{{WS}}

Revision as of 21:20, 30 January 2014


Cilostazol
PLETAL® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Studies
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

For patient information, click here.

Overview

Category

PLETAL

US Brand Names

FDA Package Insert

| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References

Retrieved from "https://www.wikidoc.org/index.php?title=Cilostazol_detailed_information&oldid=936163"